Search results
Results From The WOW.Com Content Network
The inaugural CyberKnife system was installed at Stanford University in 1991, receiving clearance for clinical investigation by the U.S. Food and Drug Administration (FDA) in 1994. Following extensive clinical research, the FDA granted approval for the treatment of intracranial tumors in 1999 and for tumors throughout the body in 2001 ...
Radiosurgery is surgery using radiation, [1] that is, the destruction of precisely selected areas of tissue using ionizing radiation rather than excision with a blade. Like other forms of radiation therapy (also called radiotherapy), it is usually used to treat cancer.
Intensity modulated radiation therapy (IMRT) is an advanced radiotherapy technique used to minimize the amount of normal tissue being irradiated in the treatment field. In some systems, this intensity modulation is achieved by moving the leaves in the MLC during the course of treatment, thereby delivering a radiation field with a non-uniform (i ...
Dr. Diane Heaton, Oklahoma CyberKnife's medical director, is an expert in the treatment of trigeminal neuralgia, a neurological disorder. She appeared at the 2012 annual meeting of the CyberKnife Society to present her clinical findings from a study examining pain relief in 19 trigeminal neuralgia patients following CyberKnife treatment. [3]
Radiation therapy is a local treatment that is designed to treat the defined tumour and spare the surrounding normal tissue from receiving doses above specified dose tolerances. There are many factors that may contribute to differences between the planned dose distribution and the delivered dose distribution.
These studies are comparative, noting differences between patients receiving a new device versus patients that receive spinal fusion or another previously-approved disc replacement. The below table illustrates currently-approved disc replacement devices, their approval dates, the number of approved levels for each device, and their current ...
For premium support please call: 800-290-4726 more ways to reach us
Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. [2] The bisphosphonate alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%; zoledronate reduces the risk of hip fractures by 38% and of vertebral ...